(ü 230) |
|
|
|
|
[] ITI , ٸ ʾ
캴 A ȯ ڿ ȭü, Ǵ ϱ ȵ ġ 鿪 (Immune Tolerance Induction, ITI) پ 쿡 ȿ ִٴ ǥǾ
Ȳ
2024-04-20
|
|
|
|
|
[] ŬĹ̵ , Ϻ õ 캴 ʿ ־
CREHA ӻ(NCT01808911) Ϳ ø(rituximab) 汸 ȭп ŬĹ̵(cyclophosphamide, ļ, ġ) İ õ
Ȳ
2024-04-16
|
|
|
|
|
[] Ʈġ, 캴 ȯڿ
ü Ȱ ϱ Ȱ ո带 캴 ȯڴ ü ǰ ũ Ǿ, ߰ ü Ȱ ð ִ ο ǽõ ұԸ .
Ȳ
2024-04-16
|
|
|
|
|
[] ͽôƼ, ̱ 캴B ҾƱ 㰡Ȯ
ž ͽôƼ(Ixinity, trenonacog alfa) 12 ̸ 캴 B ȯڿ ֵ ̱ ǰǾ౹(FDA) Ҵٰ . FDA ̹ Ȯ Medexus Ǹϴ 9(FIX) ü
Ȳ
2024-04-13
|
|
|
|
|
|
|
[] ̱캴ȸ, εֳ
̱캴ȸ(Hemophilia Federation of America, HFA) 4 11Ϻ 4 13ϱ 2 3ϰ ̱ εֳ εֳ 캴 (HFA 2024 Symposium) Ѵٰ Ȩ
Ȳ
2024-04-03
|
|
|
|
|
[] WFH ڸŰῬ α, 7 ο Ʈʽ ü
쿬(World Federation of Hemophilia, WFH) Ȩ ο ڸŰῬ α(Twinning Program) üǾٰ ǥϿ. WFH ڸŰῬ α Ƿ, ȯڴü, ûҳ
Ȳ
2024-03-18
|
|
|
|
|
[] , 5Ⱓ 캴 A ȿ?
3 ӻ(HAVEN3, HAVEN4) Ϳ , (Hemlibra, emicizumab-KXWH) 5Ⱓ ġᵿ ü 캴 A ȯ ϰ Ÿ.
Ȳ
2024-03-16
|
|
|
|
|
[] ε ؾ Ѵ
PC տ ɾ Ƿΰ ļӱ ϴ. ̰ ʸ ؽ ۿ Ƿΰ ϴ. 强 ȭ ߵ Ǿ ۾ Ұϴ.
Ȳ
2024-03-12
|
|
|
|
|
[] ڹƮ ȯ
ij ڹƮ(Kovaltry, octocog alfa) ݰ ü (Jivi, damoctocog alfa pegol) ġ ȯϸ 캴 A ִ ΰ Ҿ ϰų
Ȳ
2024-03-11
|
|
|
|
|
[] "뺸ũ, 7ڸ ϴ ƴϾ"
Ϻ ̷ Ⱓ 뺸Ʈ(Novoeight, turoctocog alfa) 캴 A ȯ Ǽҵ带 ϰ ȿ ϰ ġ Ÿ. 뺸Ʈ 91.4%
Ȳ
2024-03-11
|
|
|
|
|
[] FDA, 캴B ġ ΰ
ڸ (Intellia Therapeutics) (Regeneron) ߹ݱ 캴 B ȯڸ CRISPR/Cas9 F9( IX) ġ Ʈϴ ΰ ȹ̶ .
Ȳ
2024-03-05
|
|
|
|
|
[] 캴 A, ϸ սǵ
ƢŰ ǽõ ұԸ , ٷ ս ݺ ϴ 캴 A ΰ ִ ִ . ħ
Ȳ
2024-03-04
|
|
|
|
|
[] , 캴 ȯ ջ ־
ο ǽõ 캴 A ȯڴ 캴 B ȯڿ ǰ ڰ ջ, Ư ߸ ջ ִ Ÿ. ߿ ȯ 캴 ġḦ
Ȳ
2024-02-28
|
|
|
|
|
[] Ƶ ֻٴÿ η ؼϰ
ϱ ư Ƶ Ϸ(Caeleb) б ϰ ȴ. 18 ǵƺ װ 캴 Ȱ ư鼭 ܰ Ѵ.״ ʵб ߸
Ȳ
2024-02-19
|
|
|
|
|
[] 캴 ε带
̾ ſ Ҿ. Ȳ ̸ ٺ ϰ ߴ. ȹ ̶ ʾҴ. ȹ Ǹ װ ʽ ߴ.
Ȳ
2024-02-16
|
|
|
|
|
[] ȯ ִ , ɰ ־
ij 캴 Ÿ ȯ ִ ӽ, õ Ÿ ɼ ٰ .
Ȳ
2024-02-16
|
|
|
|
|
[] 캴 ȯڿ ֶ?
ģ ǹ , ٰ ִ. ϴ ̳ Ĭ ̱ ϴ. õ ȭ̰ų ȭ
Ȳ
2024-02-13
|
|
|
|
|
[] WFH, ڸī ȭ ̲
쿬(World Federation of Hemophilia, WFH) Ȩ ڸī ε α Ұ Ҹ ̷ٰ . WFH ٽ ǥ ϳν
Ȳ
2024-02-13
|
|
|
|
|
[] ʴ ֵ ִ ȸ ⸦
Ƶ Ϸ 8̾ , ü ̿ . ġ ü ΰ ִ ״ 캴 A ̵ ־ ߸ ջ Ծ.
Ȳ
2024-02-06
|
|
|